SYNTHETIC DEMONSTRATION — no real student or patient. Not a medical device.

Weight & metabolism

Do You Qualify for Weight Loss Medication?

Most prescription weight loss medications are approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher plus at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. A clinician reviews your full medical history to decide if a specific drug is appropriate.

Talk to a clinician

Nina Osei, NP — Nurse Practitioner

checkups, refills & skin. Gale can match you with a licensed clinician for a visit.

Find care →

What is the general eligibility framework for weight loss medications?

The FDA has approved several prescription weight loss medications. While each drug has its own specific prescribing label, the most commonly used eligibility thresholds are 12:

  • BMI of 30 or above (classified as obesity), regardless of other conditions
  • BMI of 27 to 29.9 (overweight) combined with at least one weight-related health condition — called a comorbidity

Common qualifying comorbidities include type 2 diabetes or prediabetes, high blood pressure, high cholesterol or triglycerides, obstructive sleep apnea, and cardiovascular disease.

BMI is an imperfect tool — it does not account for muscle mass or body composition — but it remains the clinical standard for initial eligibility screening 2.

What are GLP-1 receptor agonists, and what makes someone eligible?

GLP-1 receptor agonists have received significant attention because of their effectiveness in clinical trials. Semaglutide (Wegovy for weight loss, Ozempic for type 2 diabetes) and tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) are the most widely used.

They work by mimicking gut hormones that signal fullness, slow stomach emptying, and reduce appetite. In the STEP 1 trial, semaglutide produced substantial average weight loss compared with placebo in adults with obesity or overweight with at least one weight-related condition 3. In the SURMOUNT-1 trial, tirzepatide produced even larger average reductions 4.

The prescribing criteria for Wegovy and Zepbound mirror the general framework: BMI 30+, or BMI 27+ with a qualifying condition 56. These are injectable medications, taken once weekly.

They are not appropriate for everyone. People with a personal or family history of medullary thyroid cancer or a rare genetic condition called MEN2 should not take these medications. A history of pancreatitis is another factor a prescriber will evaluate 56.

What other prescription options exist?

Several oral medications are also FDA-approved for chronic weight management, including phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and orlistat. Each has different eligibility criteria, contraindications, and side effect profiles.

Phentermine alone is approved for short-term use only. Which medication, if any, is most appropriate for you depends on your other medical conditions, current medications (interaction screening), reproductive plans, and treatment goals 2.

What factors disqualify someone from these medications?

Several factors can make a specific medication inappropriate even if BMI criteria are met:

  • Pregnancy, breastfeeding, or planning pregnancy in the near future disqualifies most weight loss medications, including all GLP-1 drugs. GLP-1 drugs should be stopped at least two months before attempting pregnancy 56.
  • History of certain eating disorders warrants careful evaluation — restrictive diets and appetite-suppressing medications can interact with disordered eating patterns
  • Kidney or liver disease, heart arrhythmias, certain psychiatric conditions, and specific drug interactions are factors a prescriber will evaluate
  • Thyroid cancer history (personal or family history of medullary thyroid carcinoma) is a specific contraindication for GLP-1 drugs 5

None of these are automatic disqualifiers for all medications, but they significantly shape which option is safe for a specific person.

What does a weight management evaluation actually involve?

A weight management visit is typically thorough. The clinician will measure your height, weight, and BMI; take a detailed medical and medication history; order basic labs if not recently done; and discuss your history with diet and lifestyle approaches.

They will also set realistic expectations: most approved drugs produce meaningful but not dramatic weight loss for most people 34, and are intended to supplement — not replace — changes in eating and activity patterns. If the medication is stopped, a significant portion of lost weight typically returns over time 7.

Insurance coverage is often discussed at this visit as well, since GLP-1 medications carry high list prices and coverage varies significantly by plan 2.

What is the current picture on cost and coverage?

GLP-1 medications like Wegovy and Zepbound have high list prices. Insurance coverage depends heavily on your plan — many employer-sponsored plans do not currently cover weight loss medications, and Medicare Part D does not cover most weight loss drugs (with limited exceptions for those with established cardiovascular disease) 2.

The SELECT trial demonstrated that semaglutide reduced serious cardiovascular events in people with obesity and established cardiovascular disease but without diabetes 8. This cardiovascular benefit data has shifted some insurer coverage decisions.

Manufacturer savings programs exist but have income and insurance eligibility requirements. If cost is a concern, discuss it explicitly with your prescribing clinician — older, less expensive options may be appropriate alternatives.

Common questions

Does my BMI alone qualify me for Wegovy or Zepbound?

A BMI of 30 or above is the standard BMI threshold for eligibility, assuming no disqualifying contraindications. A BMI of 27 to 29.9 can qualify if you also have at least one weight-related health condition. Your clinician will review your full medical history, not just your BMI, before prescribing.

Will the weight come back if I stop taking a GLP-1 medication?

Clinical evidence shows that a significant portion of weight lost on semaglutide returns after stopping the medication. The STEP 1 extension study found substantial weight regain in participants who discontinued treatment. This is important context for understanding these medications as long-term therapies rather than short-term fixes.

Is my insurance likely to cover weight loss medication?

Coverage varies widely. Many employer-sponsored plans do not cover weight loss medications. Medicare Part D generally does not, with some exceptions for people with cardiovascular disease. Your prescribing clinician can help with a prior authorization letter if your plan requires one, and can discuss alternatives if the medication is not covered.

Can I get these medications if I have type 2 diabetes?

Yes — GLP-1 drugs are approved for both type 2 diabetes and weight loss. If you have diabetes, your insurance is more likely to cover an in-class medication under its diabetes brand name. The dosing may differ from the weight-loss formulation. A clinician will determine which option is most appropriate given your full situation.

What labs does a clinician typically order before prescribing weight loss medication?

Common baseline tests include fasting blood glucose and HbA1c (to screen for diabetes), a lipid panel, kidney and liver function tests, thyroid-stimulating hormone (TSH), and a blood pressure measurement. These help establish eligibility, screen for contraindications, and set a baseline for monitoring.

Talk to a clinician

Nina Osei, NP — Nurse Practitioner

checkups, refills & skin. Gale can match you with a licensed clinician for a visit.

Find care →

Important considerations before starting weight loss medication

  • —Severe abdominal pain — particularly radiating to the back — while taking a GLP-1 medication may suggest pancreatitis and warrants prompt medical evaluation
  • —Signs of a severe allergic reaction after any injection: difficulty breathing, rapid heart rate, swelling of the face or throat — call 911
  • —Any signs of thyroid nodule or neck swelling while on a GLP-1 drug should be reported to your clinician promptly

This article is general health education and does not constitute a diagnosis, prescription recommendation, or determination of eligibility for any medication. Only a licensed clinician who has reviewed your full medical history can determine whether a weight loss medication is appropriate for you.

References

  1. 1.National Institute of Diabetes and Digestive and Kidney Diseases (2023). Prescription Medications to Treat Overweight and Obesity. NIDDK / NIH. link ✓General eligibility framework for prescription weight loss medications, BMI thresholds, and available medication classes
  2. 2.Eisenberg D, Shikora SA, Aarts E, et al. (2022). 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. doi:10.1016/j.soard.2022.08.013 ✓BMI and comorbidity criteria for obesity treatment eligibility, and the clinical evaluation framework for obesity pharmacotherapy
  3. 3.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. doi:10.1056/NEJMoa2032183 ✓Semaglutide efficacy for weight loss in adults with overweight or obesity with qualifying comorbidities, and the clinical trial evidence base for Wegovy eligibility
  4. 4.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. doi:10.1056/NEJMoa2206038 ✓Tirzepatide efficacy for weight loss in adults with obesity, supporting the evidence base for Zepbound eligibility criteria
  5. 5.Novo Nordisk (2024). WEGOVY (semaglutide) injection — FDA Prescribing Information. DailyMed / FDA. link ✓FDA-approved prescribing criteria for semaglutide (Wegovy), including BMI thresholds, contraindications (thyroid cancer history, MEN2, pancreatitis), and pregnancy restrictions
  6. 6.Eli Lilly (2023). ZEPBOUND (tirzepatide) injection for Chronic Weight Management — FDA Prescribing Information. FDA / AccessData. link ✓FDA-approved prescribing criteria for tirzepatide (Zepbound), including BMI thresholds, contraindications, and pregnancy restrictions
  7. 7.Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. doi:10.1111/dom.14725 ✓Weight regain after stopping semaglutide, supporting the framing of GLP-1 medications as long-term rather than short-term therapies
  8. 8.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. doi:10.1056/NEJMoa2307563 ✓Cardiovascular benefit of semaglutide in people with obesity and established cardiovascular disease without diabetes, informing insurance coverage context

8 sources, numbered by first appearance. General health information, not medical advice — synthetic demonstration content.